DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Boerse Frankfurt Warrants 11:32:03 26/06/2024 pm IST | ||
| 0.66 EUR | -4.35% |
|
| Current month | +32.00% | ||
| 1 month | +20.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 0.66 | -4.35% |
| 25/24/25 | 0.69 | +11.29% |
| 24/24/24 | 0.62 | 0.00% |
| 21/24/21 | 0.62 | +1.64% |
| 20/24/20 | 0.61 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 11:32 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1UNB |
| ISIN | DE000VD1UNB6 |
| Date issued | 07/03/2024 |
| Strike | 160 $ |
| Maturity | 20/06/2025 (359 Days) |
| Parity | 10 : 1 |
| Emission price | 0.37 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.71 € |
|---|---|
| Lowest since issue | 0.38 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
938.1
DKK
Spread / Average Target
-6.84%
- Stock Market
- Certificates
- Certificat
